Does angiotensin-1 converting enzyme genotype influence motor or cognitive development after pre-term birth?
ABSTRACT : BACKGROUND : Raised activity of the renin-angiotensin system (RAS) may both amplify inflammatory and free radical responses and decrease tissue metabolic efficiency and thus enhance cerebral injury in the preterm infant. The angiotensin-converting enzyme (ACE) DD genotype is associated with raised ACE and RAS activity as well as potentially adverse stimuli such as inflammation. The DD genotype has been associated with neurological impairments in the elderly, and thus may be also associated with poorer motor or cognitive development amongst children born preterm prematurely. METHODS : The association of DD genotype with developmental progress amongst 176 Caucasian children born at less than 33 weeks gestation (median birthweight 1475 g, range 645-2480 g; gestation 30 weeks, range 22-32; 108 male) was examined at 2 and 5 1/2 years of age. Measured neuro-cognitive outcomes were cranial ultrasound abnormalities, cerebral palsy, disability, Griffiths Developmental Quotient [DQ] at 2 yrs, and General Cognitive Ability [British Ability Scales-11] and motor performance [ABC Movement], both performed at 5 1/2 yrs. All outcomes were correlated with ACE genotype. RESULTS : The DD genotype was not associated with lower developmental quotients even after accounting for important social variables. CONCLUSION : These data do not support either a role for ACE in the development of cognitive or motor function in surviving infants born preterm or inhibition of ACE as a neuroprotective therapy.
Harding
David R
DR
Neonatal Intensive Care Unit, St, Michael's Hospital, Bristol, UK. david.harding@bristol.ac.uk.
Dhamrait
Sukhbir
S
Devadason
David
D
Humphries
Steve E
SE
Whitelaw
Andrew
A
Marlow
Neil
N
Montgomery
Hugh E
HE
Nature. 2000 Feb 10;403(6770):614
10688186
J Pediatr. 2003 Dec;143(6):746-9
14657821
Neurosci Lett. 2000 Sep 1;290(3):177-80
10963892
Arch Dis Child Fetal Neonatal Ed. 1998 Jul;79(1):F4-11
9797618
Neuropediatrics. 1993 Oct;24(5):263-8
8309515
Circulation. 1999 Sep 21;100(12):1291-7
10491373
Lancet. 1999 May 15;353(9165):1653-7
10335784
J Neuropathol Exp Neurol. 1997 Mar;56(3):219-35
9056536
Semin Neonatol. 2000 Feb;5(1):3-16
10802746
Dev Med Child Neurol. 1998 Oct;40(10):652-60
9851233
Am J Obstet Gynecol. 1997 Jul;177(1):19-26
9240577
Biochem J. 1993 Feb 15;290 ( Pt 1):33-40
8382480
Neuropeptides. 2001 Feb;35(1):65-9
11346312
Arch Neurol. 2000 Feb;57(2):210-4
10681079
Neurosci Lett. 1999 May 28;267(2):97-100
10400221
Eur J Pharmacol. 1999 May 28;373(1):21-33
10408248
N Engl J Med. 2000 Aug 10;343 (6):378-84
10933736
Neurology. 2004 Oct 12;63(7):1324-5
15477567
Int J Dev Neurosci. 2004 Nov;22(7):475-84
15465277
J Clin Invest. 1990 Oct;86(4):1343-6
1976655